

<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <roleRef roleURI="http://www.tekmirapharm.com/role/CollaborationsContractsAndLicensingAgreements" xlink:href="abus-20151231.xsd#CollaborationsContractsAndLicensingAgreements" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/CollaborationsContractsAndLicensingAgreementsDeferredCollaborationsAndContractsRevenueDetails" xlink:href="abus-20151231.xsd#CollaborationsContractsAndLicensingAgreementsDeferredCollaborationsAndContractsRevenueDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/CollaborationsContractsAndLicensingAgreementsDetails" xlink:href="abus-20151231.xsd#CollaborationsContractsAndLicensingAgreementsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/CollaborationsContractsAndLicensingAgreementsRevenueRecognizedUnderCollaborationsContractsAndLicensingAgreementsDetails" xlink:href="abus-20151231.xsd#CollaborationsContractsAndLicensingAgreementsRevenueRecognizedUnderCollaborationsContractsAndLicensingAgreementsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/CollaborationsContractsAndLicensingAgreementsTables" xlink:href="abus-20151231.xsd#CollaborationsContractsAndLicensingAgreementsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ConcentrationsOfBusinessRisk" xlink:href="abus-20151231.xsd#ConcentrationsOfBusinessRisk" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ConcentrationsOfBusinessRiskDetails" xlink:href="abus-20151231.xsd#ConcentrationsOfBusinessRiskDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ConcentrationsOfBusinessRiskForeignCurrencyExposureDetails" xlink:href="abus-20151231.xsd#ConcentrationsOfBusinessRiskForeignCurrencyExposureDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ConcentrationsOfBusinessRiskNetLiquidityOfCompanyDetails" xlink:href="abus-20151231.xsd#ConcentrationsOfBusinessRiskNetLiquidityOfCompanyDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ConcentrationsOfBusinessRiskTables" xlink:href="abus-20151231.xsd#ConcentrationsOfBusinessRiskTables" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ConsolidatedBalanceSheets" xlink:href="abus-20151231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="abus-20151231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ConsolidatedStatementOfStockholdersEquity" xlink:href="abus-20151231.xsd#ConsolidatedStatementOfStockholdersEquity" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ConsolidatedStatementOfStockholdersEquityParenthetical" xlink:href="abus-20151231.xsd#ConsolidatedStatementOfStockholdersEquityParenthetical" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="abus-20151231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="abus-20151231.xsd#ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ContingenciesAndCommitments" xlink:href="abus-20151231.xsd#ContingenciesAndCommitments" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ContingenciesAndCommitmentsDetails" xlink:href="abus-20151231.xsd#ContingenciesAndCommitmentsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ContingenciesAndCommitmentsMinimumRentAndEstimatedOperatingCostCommitmentNetLeaseInducementsDetails" xlink:href="abus-20151231.xsd#ContingenciesAndCommitmentsMinimumRentAndEstimatedOperatingCostCommitmentNetLeaseInducementsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ContingenciesAndCommitmentsTables" xlink:href="abus-20151231.xsd#ContingenciesAndCommitmentsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/DocumentAndEntityInformation" xlink:href="abus-20151231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/GovernmentGrantsAndRefundableInvestmentTaxCredits" xlink:href="abus-20151231.xsd#GovernmentGrantsAndRefundableInvestmentTaxCredits" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/GovernmentGrantsAndRefundableInvestmentTaxCreditsDetails" xlink:href="abus-20151231.xsd#GovernmentGrantsAndRefundableInvestmentTaxCreditsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/IncomeTaxes" xlink:href="abus-20151231.xsd#IncomeTaxes" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/IncomeTaxesDeferredTaxAssetsDetails" xlink:href="abus-20151231.xsd#IncomeTaxesDeferredTaxAssetsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/IncomeTaxesDetails" xlink:href="abus-20151231.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/IncomeTaxesIncomeTaxReconciliationDetails" xlink:href="abus-20151231.xsd#IncomeTaxesIncomeTaxReconciliationDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/IncomeTaxesTables" xlink:href="abus-20151231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/InterimFinancialDataUnaudited" xlink:href="abus-20151231.xsd#InterimFinancialDataUnaudited" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/InterimFinancialDataUnauditedDetails" xlink:href="abus-20151231.xsd#InterimFinancialDataUnauditedDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/InterimFinancialDataUnauditedTables" xlink:href="abus-20151231.xsd#InterimFinancialDataUnauditedTables" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaInc" xlink:href="abus-20151231.xsd#MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaInc" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncCarryingValueOfIntangibleAssetsAfterImpairmentDetails" xlink:href="abus-20151231.xsd#MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncCarryingValueOfIntangibleAssetsAfterImpairmentDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncNarrativeDetails" xlink:href="abus-20151231.xsd#MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncNarrativeDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncProFormaInformationDetails" xlink:href="abus-20151231.xsd#MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncProFormaInformationDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncPurchasePriceAllocationDetails" xlink:href="abus-20151231.xsd#MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncPurchasePriceAllocationDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncReconciliationOfPreliminaryToFinalPurchasePriceAllocationDetails" xlink:href="abus-20151231.xsd#MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncReconciliationOfPreliminaryToFinalPurchasePriceAllocationDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncSummaryOfAcquiredIdentifiableIntangibleAssetsDetails" xlink:href="abus-20151231.xsd#MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncSummaryOfAcquiredIdentifiableIntangibleAssetsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncTables" xlink:href="abus-20151231.xsd#MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncTables" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/NatureOfBusinessAndFutureOperations" xlink:href="abus-20151231.xsd#NatureOfBusinessAndFutureOperations" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/NatureOfBusinessAndFutureOperationsNarrativeDetails" xlink:href="abus-20151231.xsd#NatureOfBusinessAndFutureOperationsNarrativeDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/PropertyAndEquipment" xlink:href="abus-20151231.xsd#PropertyAndEquipment" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/PropertyAndEquipmentDetails" xlink:href="abus-20151231.xsd#PropertyAndEquipmentDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/PropertyAndEquipmentPropertyAndEquipmentSummaryDetails" xlink:href="abus-20151231.xsd#PropertyAndEquipmentPropertyAndEquipmentSummaryDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/PropertyAndEquipmentTables" xlink:href="abus-20151231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ShareCapital" xlink:href="abus-20151231.xsd#ShareCapital" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ShareCapitalBlackScholesOptionPricingAssumptionsDetails" xlink:href="abus-20151231.xsd#ShareCapitalBlackScholesOptionPricingAssumptionsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ShareCapitalDetails" xlink:href="abus-20151231.xsd#ShareCapitalDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ShareCapitalLocationOfExpensesForStockBasedCompensationDetails" xlink:href="abus-20151231.xsd#ShareCapitalLocationOfExpensesForStockBasedCompensationDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ShareCapitalNonVestedStockOptionActivityDetails" xlink:href="abus-20151231.xsd#ShareCapitalNonVestedStockOptionActivityDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ShareCapitalNonVestedStockOptionActivityOncoreOptionPlanDetails" xlink:href="abus-20151231.xsd#ShareCapitalNonVestedStockOptionActivityOncoreOptionPlanDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ShareCapitalOutstandingOptionsUnderOncoreOptionPlanDetails" xlink:href="abus-20151231.xsd#ShareCapitalOutstandingOptionsUnderOncoreOptionPlanDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ShareCapitalOutstandingOptionsUnderProtivaOptionPlanDetails" xlink:href="abus-20151231.xsd#ShareCapitalOutstandingOptionsUnderProtivaOptionPlanDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ShareCapitalStockOptionActivityDetails" xlink:href="abus-20151231.xsd#ShareCapitalStockOptionActivityDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ShareCapitalStockOptionsOutstandingDetails" xlink:href="abus-20151231.xsd#ShareCapitalStockOptionsOutstandingDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ShareCapitalSummaryOfWarrantActivityDetails" xlink:href="abus-20151231.xsd#ShareCapitalSummaryOfWarrantActivityDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ShareCapitalTables" xlink:href="abus-20151231.xsd#ShareCapitalTables" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ShareCapitalWeightedAverageOptionPricingAssumptionsDetails" xlink:href="abus-20151231.xsd#ShareCapitalWeightedAverageOptionPricingAssumptionsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/SignificantAccountingPolicies" xlink:href="abus-20151231.xsd#SignificantAccountingPolicies" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="abus-20151231.xsd#SignificantAccountingPoliciesAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesChangesInFairValueOfCompanysWarrantsDetails" xlink:href="abus-20151231.xsd#SignificantAccountingPoliciesChangesInFairValueOfCompanysWarrantsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesChangesInFairValueOfContingentConsiderationDetails" xlink:href="abus-20151231.xsd#SignificantAccountingPoliciesChangesInFairValueOfContingentConsiderationDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesComputationOfBasicAndDilutedNetIncomeLossPerCommonShareDetails" xlink:href="abus-20151231.xsd#SignificantAccountingPoliciesComputationOfBasicAndDilutedNetIncomeLossPerCommonShareDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesEstimatedUsefulLivesDetails" xlink:href="abus-20151231.xsd#SignificantAccountingPoliciesEstimatedUsefulLivesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:href="abus-20151231.xsd#SignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesPolicies" xlink:href="abus-20151231.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesTables" xlink:href="abus-20151231.xsd#SignificantAccountingPoliciesTables" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/SubsequentEvents" xlink:href="abus-20151231.xsd#SubsequentEvents" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/SubsequentEventsDetails" xlink:href="abus-20151231.xsd#SubsequentEventsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/SupplementaryInformation" xlink:href="abus-20151231.xsd#SupplementaryInformation" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/SupplementaryInformationDetails" xlink:href="abus-20151231.xsd#SupplementaryInformationDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/SupplementaryInformationTables" xlink:href="abus-20151231.xsd#SupplementaryInformationTables" xlink:type="simple" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/CollaborationsContractsAndLicensingAgreements" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/CollaborationsContractsAndLicensingAgreementsDeferredCollaborationsAndContractsRevenueDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/CollaborationsContractsAndLicensingAgreementsDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/CollaborationsContractsAndLicensingAgreementsRevenueRecognizedUnderCollaborationsContractsAndLicensingAgreementsDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/CollaborationsContractsAndLicensingAgreementsTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/ConcentrationsOfBusinessRisk" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/ConcentrationsOfBusinessRiskDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/ConcentrationsOfBusinessRiskForeignCurrencyExposureDetails" xlink:type="extended">
    <loc xlink:href="abus-20151231.xsd#abus_ExposureToUSDollar" xlink:label="loc_abus_ExposureToUSDollar_a6f969da-810c-7e02-672b-ef6337763489" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_99cc497a-24d6-394d-7b8f-e0bd0a50eba0" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_abus_ExposureToUSDollar_a6f969da-810c-7e02-672b-ef6337763489" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_99cc497a-24d6-394d-7b8f-e0bd0a50eba0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsReceivableNet" xlink:label="loc_us-gaap_AccountsReceivableNet_3524be21-eaec-4398-eb0d-fe71dbe67324" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_abus_ExposureToUSDollar_a6f969da-810c-7e02-672b-ef6337763489" xlink:to="loc_us-gaap_AccountsReceivableNet_3524be21-eaec-4398-eb0d-fe71dbe67324" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnbilledReceivablesCurrent" xlink:label="loc_us-gaap_UnbilledReceivablesCurrent_01c79cd5-7db4-c322-4828-4ad1d3c115b4" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_abus_ExposureToUSDollar_a6f969da-810c-7e02-672b-ef6337763489" xlink:to="loc_us-gaap_UnbilledReceivablesCurrent_01c79cd5-7db4-c322-4828-4ad1d3c115b4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_3185ab5b-1aca-212d-4c91-70e5620fe0fb" xlink:type="locator" />
    <calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_abus_ExposureToUSDollar_a6f969da-810c-7e02-672b-ef6337763489" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_3185ab5b-1aca-212d-4c91-70e5620fe0fb" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/ConcentrationsOfBusinessRiskNetLiquidityOfCompanyDetails" xlink:type="extended">
    <loc xlink:href="abus-20151231.xsd#abus_NetLiquidity" xlink:label="loc_abus_NetLiquidity_3dc9ec35-4578-627a-c6d9-ef633774e06e" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_99cc497a-24d6-394d-7b8f-e0bd0a50eba0" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_abus_NetLiquidity_3dc9ec35-4578-627a-c6d9-ef633774e06e" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_99cc497a-24d6-394d-7b8f-e0bd0a50eba0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_3185ab5b-1aca-212d-4c91-70e5620fe0fb" xlink:type="locator" />
    <calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_abus_NetLiquidity_3dc9ec35-4578-627a-c6d9-ef633774e06e" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_3185ab5b-1aca-212d-4c91-70e5620fe0fb" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/ConcentrationsOfBusinessRiskTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_ae9fd5e7-8741-dfbd-241e-1460ec6c786e" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_16ce0436-3b82-55c5-d896-5cba4c9023bd" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_ae9fd5e7-8741-dfbd-241e-1460ec6c786e" xlink:to="loc_us-gaap_Liabilities_16ce0436-3b82-55c5-d896-5cba4c9023bd" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_1477e02d-b6d8-3df6-e715-8364fedce6d9" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_16ce0436-3b82-55c5-d896-5cba4c9023bd" xlink:to="loc_us-gaap_LiabilitiesCurrent_1477e02d-b6d8-3df6-e715-8364fedce6d9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_771fda46-ad18-43f7-74a8-24b4258a1976" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1477e02d-b6d8-3df6-e715-8364fedce6d9" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_771fda46-ad18-43f7-74a8-24b4258a1976" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_c952180c-d37a-a6b0-3e18-a18cd8328eee" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1477e02d-b6d8-3df6-e715-8364fedce6d9" xlink:to="loc_us-gaap_DeferredRevenueCurrent_c952180c-d37a-a6b0-3e18-a18cd8328eee" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_ce979c60-36c9-c8c1-cd3c-341cd1a8c7d0" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1477e02d-b6d8-3df6-e715-8364fedce6d9" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_ce979c60-36c9-c8c1-cd3c-341cd1a8c7d0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_e71e7b37-2828-6759-f8ce-a5ac289c852b" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_16ce0436-3b82-55c5-d896-5cba4c9023bd" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_e71e7b37-2828-6759-f8ce-a5ac289c852b" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_2f75413a-0715-3e2a-7260-1e1c79d9f7ef" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_16ce0436-3b82-55c5-d896-5cba4c9023bd" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_2f75413a-0715-3e2a-7260-1e1c79d9f7ef" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_43aaac76-959d-69e2-234b-7c7a89d77345" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_16ce0436-3b82-55c5-d896-5cba4c9023bd" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_43aaac76-959d-69e2-234b-7c7a89d77345" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_26e56c7a-24ab-e869-809a-0509ccbe86d9" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_ae9fd5e7-8741-dfbd-241e-1460ec6c786e" xlink:to="loc_us-gaap_StockholdersEquity_26e56c7a-24ab-e869-809a-0509ccbe86d9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_ffd09989-75a8-4713-beb0-21bebb3561d6" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_26e56c7a-24ab-e869-809a-0509ccbe86d9" xlink:to="loc_us-gaap_CommonStockValue_ffd09989-75a8-4713-beb0-21bebb3561d6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_dcbd5d14-4ec6-06fe-e5c1-a41efced6761" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_26e56c7a-24ab-e869-809a-0509ccbe86d9" xlink:to="loc_us-gaap_AdditionalPaidInCapital_dcbd5d14-4ec6-06fe-e5c1-a41efced6761" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_440a13e9-e4dc-f397-4d0d-27daacd44483" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_26e56c7a-24ab-e869-809a-0509ccbe86d9" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_440a13e9-e4dc-f397-4d0d-27daacd44483" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4d60b95b-a2a9-55da-7eaa-2ca718a58484" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_26e56c7a-24ab-e869-809a-0509ccbe86d9" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4d60b95b-a2a9-55da-7eaa-2ca718a58484" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_b517a4f1-4597-b094-2608-75af660328e1" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_a1eaafaf-055b-e423-85ef-4424fb2ef4e4" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b517a4f1-4597-b094-2608-75af660328e1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_a1eaafaf-055b-e423-85ef-4424fb2ef4e4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_c4121e9a-097d-7136-dbac-b93469330286" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_a1eaafaf-055b-e423-85ef-4424fb2ef4e4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_c4121e9a-097d-7136-dbac-b93469330286" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2c0591e3-817a-5563-df1e-5c3ede33266d" xlink:type="locator" />
    <calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_a1eaafaf-055b-e423-85ef-4424fb2ef4e4" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2c0591e3-817a-5563-df1e-5c3ede33266d" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments_c62110c4-28c7-e8eb-2a6d-e8964607a348" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b517a4f1-4597-b094-2608-75af660328e1" xlink:to="loc_us-gaap_LongTermInvestments_c62110c4-28c7-e8eb-2a6d-e8964607a348" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_32ecd7de-6410-d56f-5547-ab1b682ebbc0" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b517a4f1-4597-b094-2608-75af660328e1" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_32ecd7de-6410-d56f-5547-ab1b682ebbc0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_d1288432-0516-3188-e96b-2bc623375a5a" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b517a4f1-4597-b094-2608-75af660328e1" xlink:to="loc_us-gaap_Goodwill_d1288432-0516-3188-e96b-2bc623375a5a" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_67f49e84-05fd-4b0b-ae5a-e9913b97cea2" xlink:type="locator" />
    <calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b517a4f1-4597-b094-2608-75af660328e1" xlink:to="loc_us-gaap_AssetsCurrent_67f49e84-05fd-4b0b-ae5a-e9913b97cea2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_999960f8-6702-f7e9-88df-fcb8021751b2" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_67f49e84-05fd-4b0b-ae5a-e9913b97cea2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_999960f8-6702-f7e9-88df-fcb8021751b2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_96e417a6-7446-6031-787d-9a81025423eb" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_67f49e84-05fd-4b0b-ae5a-e9913b97cea2" xlink:to="loc_us-gaap_ShortTermInvestments_96e417a6-7446-6031-787d-9a81025423eb" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_dc301a2a-78b3-2f7c-72b2-6d5ec18f9327" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_67f49e84-05fd-4b0b-ae5a-e9913b97cea2" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_dc301a2a-78b3-2f7c-72b2-6d5ec18f9327" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnbilledReceivablesCurrent" xlink:label="loc_us-gaap_UnbilledReceivablesCurrent_01c79cd5-7db4-c322-4828-4ad1d3c115b4" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_67f49e84-05fd-4b0b-ae5a-e9913b97cea2" xlink:to="loc_us-gaap_UnbilledReceivablesCurrent_01c79cd5-7db4-c322-4828-4ad1d3c115b4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="loc_us-gaap_IncomeTaxesReceivable_b55f8997-2ee7-02b3-cb5b-06e177e6e17d" xlink:type="locator" />
    <calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_67f49e84-05fd-4b0b-ae5a-e9913b97cea2" xlink:to="loc_us-gaap_IncomeTaxesReceivable_b55f8997-2ee7-02b3-cb5b-06e177e6e17d" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3227d5e9-cb9d-fda7-e599-c6fb89b5e07a" xlink:type="locator" />
    <calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_67f49e84-05fd-4b0b-ae5a-e9913b97cea2" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3227d5e9-cb9d-fda7-e599-c6fb89b5e07a" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/ConsolidatedStatementOfStockholdersEquity" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/ConsolidatedStatementOfStockholdersEquityParenthetical" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_46b895b2-8ff5-9e37-d4c3-5b75649cbcba" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b6b5c2f7-2ab7-a264-6d06-119dda52768c" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_46b895b2-8ff5-9e37-d4c3-5b75649cbcba" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b6b5c2f7-2ab7-a264-6d06-119dda52768c" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fb013d5f-7e0c-1a40-5a42-42bd8c3a1d51" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_46b895b2-8ff5-9e37-d4c3-5b75649cbcba" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fb013d5f-7e0c-1a40-5a42-42bd8c3a1d51" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsForProceedsFromInvestments" xlink:label="loc_us-gaap_PaymentsForProceedsFromInvestments_5ad9674a-6203-3e3a-f329-f4cfb3162c67" xlink:type="locator" />
    <calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fb013d5f-7e0c-1a40-5a42-42bd8c3a1d51" xlink:to="loc_us-gaap_PaymentsForProceedsFromInvestments_5ad9674a-6203-3e3a-f329-f4cfb3162c67" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_af325b40-4a9e-bc21-ac47-5d226ccd5482" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fb013d5f-7e0c-1a40-5a42-42bd8c3a1d51" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_af325b40-4a9e-bc21-ac47-5d226ccd5482" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_90abc8df-a70a-7c23-5fff-9b3d9bc98c9b" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fb013d5f-7e0c-1a40-5a42-42bd8c3a1d51" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_90abc8df-a70a-7c23-5fff-9b3d9bc98c9b" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_37181af6-e562-cefc-f2b6-8490ea2c3e04" xlink:type="locator" />
    <calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fb013d5f-7e0c-1a40-5a42-42bd8c3a1d51" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_37181af6-e562-cefc-f2b6-8490ea2c3e04" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6d7b73b6-0db7-23f7-377e-417fa8fc8e27" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_46b895b2-8ff5-9e37-d4c3-5b75649cbcba" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6d7b73b6-0db7-23f7-377e-417fa8fc8e27" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_bdec3780-88f3-c634-f85d-cb36bba63bd2" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6d7b73b6-0db7-23f7-377e-417fa8fc8e27" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_bdec3780-88f3-c634-f85d-cb36bba63bd2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_29d765d3-9bf3-69a0-f67a-85487c765b79" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6d7b73b6-0db7-23f7-377e-417fa8fc8e27" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_29d765d3-9bf3-69a0-f67a-85487c765b79" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_60196f93-012a-e451-c3d1-1aecefe41f32" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6d7b73b6-0db7-23f7-377e-417fa8fc8e27" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_60196f93-012a-e451-c3d1-1aecefe41f32" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_21149c4c-60e9-1f3a-82d3-665a83a5c4f2" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_46b895b2-8ff5-9e37-d4c3-5b75649cbcba" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_21149c4c-60e9-1f3a-82d3-665a83a5c4f2" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_375e0d17-4818-4239-a370-aada0b6ca8eb" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_7fd63b12-05a5-a417-a943-a2dd6e58d717" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_375e0d17-4818-4239-a370-aada0b6ca8eb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_7fd63b12-05a5-a417-a943-a2dd6e58d717" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_faecc408-4bea-6e13-83bd-71b4c2ddf64c" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_375e0d17-4818-4239-a370-aada0b6ca8eb" xlink:to="loc_us-gaap_NetIncomeLoss_faecc408-4bea-6e13-83bd-71b4c2ddf64c" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_10afc0e9-1faa-0be3-fc32-15d128e46f3f" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_faecc408-4bea-6e13-83bd-71b4c2ddf64c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_10afc0e9-1faa-0be3-fc32-15d128e46f3f" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_72b2c986-6e1a-bdde-cc72-888b0df562b9" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_10afc0e9-1faa-0be3-fc32-15d128e46f3f" xlink:to="loc_us-gaap_OperatingIncomeLoss_72b2c986-6e1a-bdde-cc72-888b0df562b9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_467b5ef7-2b02-661a-3e41-f79140739819" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_72b2c986-6e1a-bdde-cc72-888b0df562b9" xlink:to="loc_us-gaap_Revenues_467b5ef7-2b02-661a-3e41-f79140739819" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="loc_us-gaap_ContractsRevenue_6e350f7a-ab47-e4cf-c75e-0634d95fc8b2" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_467b5ef7-2b02-661a-3e41-f79140739819" xlink:to="loc_us-gaap_ContractsRevenue_6e350f7a-ab47-e4cf-c75e-0634d95fc8b2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaap_LicensesRevenue_897c0d66-1163-53d3-0580-29e565de71d0" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_467b5ef7-2b02-661a-3e41-f79140739819" xlink:to="loc_us-gaap_LicensesRevenue_897c0d66-1163-53d3-0580-29e565de71d0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_ee2bd36d-150a-7303-38c4-eb755f792210" xlink:type="locator" />
    <calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_72b2c986-6e1a-bdde-cc72-888b0df562b9" xlink:to="loc_us-gaap_OperatingExpenses_ee2bd36d-150a-7303-38c4-eb755f792210" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_7d1bc05d-33ee-c009-4533-b70ee0a74dc9" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_ee2bd36d-150a-7303-38c4-eb755f792210" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_7d1bc05d-33ee-c009-4533-b70ee0a74dc9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_7c6d12de-ee49-8fea-ba36-2f44ccb8dae4" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_ee2bd36d-150a-7303-38c4-eb755f792210" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_7c6d12de-ee49-8fea-ba36-2f44ccb8dae4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_296ac298-3acc-b888-34a0-99e6da446889" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_ee2bd36d-150a-7303-38c4-eb755f792210" xlink:to="loc_us-gaap_Depreciation_296ac298-3acc-b888-34a0-99e6da446889" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_b4af5cc9-e22d-6655-b850-9e2926452dd4" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_ee2bd36d-150a-7303-38c4-eb755f792210" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_b4af5cc9-e22d-6655-b850-9e2926452dd4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_086246f8-2deb-77e5-5749-2b3fc6e74fb5" xlink:type="locator" />
    <calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_ee2bd36d-150a-7303-38c4-eb755f792210" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_086246f8-2deb-77e5-5749-2b3fc6e74fb5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_89191b30-59c9-0ba0-34ea-6e2a98cbdb1c" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_10afc0e9-1faa-0be3-fc32-15d128e46f3f" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_89191b30-59c9-0ba0-34ea-6e2a98cbdb1c" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_a24d82ba-62b0-7744-0b3a-f37dbe668bee" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_89191b30-59c9-0ba0-34ea-6e2a98cbdb1c" xlink:to="loc_us-gaap_InvestmentIncomeInterest_a24d82ba-62b0-7744-0b3a-f37dbe668bee" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_b3399012-62b0-7fc5-0d6c-327b1e46d7be" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_89191b30-59c9-0ba0-34ea-6e2a98cbdb1c" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_b3399012-62b0-7fc5-0d6c-327b1e46d7be" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:label="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_4c6646f7-2200-0f24-ebab-985fcfdd94a1" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_89191b30-59c9-0ba0-34ea-6e2a98cbdb1c" xlink:to="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_4c6646f7-2200-0f24-ebab-985fcfdd94a1" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability" xlink:label="loc_abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability_9C0FCAE61C37B385D6392F30CEAF7932" xlink:type="locator" />
    <calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_89191b30-59c9-0ba0-34ea-6e2a98cbdb1c" xlink:to="loc_abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability_9C0FCAE61C37B385D6392F30CEAF7932" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_3a83e980-c99b-5657-79fd-300643b7fa11" xlink:type="locator" />
    <calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_faecc408-4bea-6e13-83bd-71b4c2ddf64c" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_3a83e980-c99b-5657-79fd-300643b7fa11" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/ContingenciesAndCommitments" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/ContingenciesAndCommitmentsDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/ContingenciesAndCommitmentsMinimumRentAndEstimatedOperatingCostCommitmentNetLeaseInducementsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_cc811211-f8d9-2df0-b015-05419b9bfc99" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_a329292c-67ac-0030-2d90-e18d188691fe" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_cc811211-f8d9-2df0-b015-05419b9bfc99" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_a329292c-67ac-0030-2d90-e18d188691fe" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_d0d481f0-55e7-c97c-ec8d-df7b34e55256" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_cc811211-f8d9-2df0-b015-05419b9bfc99" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_d0d481f0-55e7-c97c-ec8d-df7b34e55256" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_b90d3e1a-4d8a-a6c8-154e-2ac9658c1ba3" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_cc811211-f8d9-2df0-b015-05419b9bfc99" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_b90d3e1a-4d8a-a6c8-154e-2ac9658c1ba3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_50b4cfc1-5417-1ddf-07f2-e739d063c669" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_cc811211-f8d9-2df0-b015-05419b9bfc99" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_50b4cfc1-5417-1ddf-07f2-e739d063c669" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/ContingenciesAndCommitmentsTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/GovernmentGrantsAndRefundableInvestmentTaxCredits" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/GovernmentGrantsAndRefundableInvestmentTaxCreditsDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/IncomeTaxes" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/IncomeTaxesDeferredTaxAssetsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_4c447841-8fe7-39fb-b3f1-0ad85920e353" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_c6255722-3158-aa8e-fb0b-718e4b04bb3b" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_4c447841-8fe7-39fb-b3f1-0ad85920e353" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_c6255722-3158-aa8e-fb0b-718e4b04bb3b" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_9afa727c-dfb8-5804-93fa-f0667d5fb87b" xlink:type="locator" />
    <calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_4c447841-8fe7-39fb-b3f1-0ad85920e353" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_9afa727c-dfb8-5804-93fa-f0667d5fb87b" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_c43448c4-6b4c-56ea-f479-78cea348bda4" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_576d5a77-ba10-3881-36d9-b5e9bdaefd1b" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_c43448c4-6b4c-56ea-f479-78cea348bda4" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_576d5a77-ba10-3881-36d9-b5e9bdaefd1b" xlink:type="arc" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_c43448c4-6b4c-56ea-f479-78cea348bda4" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_9afa727c-dfb8-5804-93fa-f0667d5fb87b" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/IncomeTaxesDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/IncomeTaxesIncomeTaxReconciliationDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_3a83e980-c99b-5657-79fd-300643b7fa11" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_6ddabc60-b949-830f-ceec-3c3166ee4678" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_3a83e980-c99b-5657-79fd-300643b7fa11" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_6ddabc60-b949-830f-ceec-3c3166ee4678" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_5be9418b-d455-e525-e892-c42da5d9af08" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_3a83e980-c99b-5657-79fd-300643b7fa11" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_5be9418b-d455-e525-e892-c42da5d9af08" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_97197894-8a5f-31b0-a37d-05c54140608d" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_3a83e980-c99b-5657-79fd-300643b7fa11" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_97197894-8a5f-31b0-a37d-05c54140608d" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_98c96f59-a5e7-5cf9-49f0-76a97dacee60" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_3a83e980-c99b-5657-79fd-300643b7fa11" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_98c96f59-a5e7-5cf9-49f0-76a97dacee60" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_1dfd4cb0-12c9-60ef-4e8f-faef112ad93a" xlink:type="locator" />
    <calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_3a83e980-c99b-5657-79fd-300643b7fa11" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_1dfd4cb0-12c9-60ef-4e8f-faef112ad93a" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/IncomeTaxesTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/InterimFinancialDataUnaudited" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/InterimFinancialDataUnauditedDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/InterimFinancialDataUnauditedTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaInc" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncCarryingValueOfIntangibleAssetsAfterImpairmentDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncNarrativeDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncProFormaInformationDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncPurchasePriceAllocationDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncReconciliationOfPreliminaryToFinalPurchasePriceAllocationDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_037c29de-ccb7-dec0-287b-acc4250657a5" xlink:type="locator" />
    <loc xlink:href="abus-20151231.xsd#abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCash" xlink:label="loc_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCash_3F925705BFB001150EC239A538441B38" xlink:type="locator" />
    <calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_037c29de-ccb7-dec0-287b-acc4250657a5" xlink:to="loc_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCash_3F925705BFB001150EC239A538441B38" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpensesandOtherAssets" xlink:label="loc_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpensesandOtherAssets_10CA3D1AE18A0F940F0D39A649386A5C" xlink:type="locator" />
    <calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_037c29de-ccb7-dec0-287b-acc4250657a5" xlink:to="loc_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpensesandOtherAssets_10CA3D1AE18A0F940F0D39A649386A5C" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccountsReceivable" xlink:label="loc_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccountsReceivable_CC68B0BCFFD4D3E227BE39A7EACDF399" xlink:type="locator" />
    <calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_037c29de-ccb7-dec0-287b-acc4250657a5" xlink:to="loc_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccountsReceivable_CC68B0BCFFD4D3E227BE39A7EACDF399" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPropertyPlantAndEquipment" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPropertyPlantAndEquipment_f944ecf8-d194-df76-9d48-a0c103c51480" xlink:type="locator" />
    <calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_037c29de-ccb7-dec0-287b-acc4250657a5" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPropertyPlantAndEquipment_f944ecf8-d194-df76-9d48-a0c103c51480" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_439e2522-10d1-8116-e942-1ae9198edc43" xlink:type="locator" />
    <calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_037c29de-ccb7-dec0-287b-acc4250657a5" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_439e2522-10d1-8116-e942-1ae9198edc43" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_be65df66-ba7c-f27f-83d4-ab2c1f0859c9" xlink:type="locator" />
    <calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_037c29de-ccb7-dec0-287b-acc4250657a5" xlink:to="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_be65df66-ba7c-f27f-83d4-ab2c1f0859c9" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccountsPayableandAccruedLiabilities" xlink:label="loc_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccountsPayableandAccruedLiabilities_7F1CCD8028C526F9E1CD39A9124EB2A0" xlink:type="locator" />
    <calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_037c29de-ccb7-dec0-287b-acc4250657a5" xlink:to="loc_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccountsPayableandAccruedLiabilities_7F1CCD8028C526F9E1CD39A9124EB2A0" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherNonCurrentLiabilities" xlink:label="loc_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherNonCurrentLiabilities_022894920530B847C71639A9E1DAB7FC" xlink:type="locator" />
    <calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_037c29de-ccb7-dec0-287b-acc4250657a5" xlink:to="loc_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherNonCurrentLiabilities_022894920530B847C71639A9E1DAB7FC" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredIncomeTaxLiability" xlink:label="loc_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredIncomeTaxLiability_B80688D3420D8CB473A539AA5ABDCFB4" xlink:type="locator" />
    <calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_037c29de-ccb7-dec0-287b-acc4250657a5" xlink:to="loc_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredIncomeTaxLiability_B80688D3420D8CB473A539AA5ABDCFB4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_5baa6f06-d5c1-e7d5-57ec-bd3b80e4bef6" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_ac0c8685-2a5b-4001-4838-de7767c606f3" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_5baa6f06-d5c1-e7d5-57ec-bd3b80e4bef6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_ac0c8685-2a5b-4001-4838-de7767c606f3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_33e8fe41-b5e8-bc8e-8934-058be6d022a1" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_5baa6f06-d5c1-e7d5-57ec-bd3b80e4bef6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_33e8fe41-b5e8-bc8e-8934-058be6d022a1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_8108f0d4-08a0-ec7c-c765-bac280e911fb" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_5baa6f06-d5c1-e7d5-57ec-bd3b80e4bef6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_8108f0d4-08a0-ec7c-c765-bac280e911fb" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_40b1481f-0626-6aa6-7abd-04c754980b6d" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_5baa6f06-d5c1-e7d5-57ec-bd3b80e4bef6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_40b1481f-0626-6aa6-7abd-04c754980b6d" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_81e8c6d9-1c93-f9e0-90a7-5f22ce1d3593" xlink:type="locator" />
    <calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_5baa6f06-d5c1-e7d5-57ec-bd3b80e4bef6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_81e8c6d9-1c93-f9e0-90a7-5f22ce1d3593" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_d1288432-0516-3188-e96b-2bc623375a5a" xlink:type="locator" />
    <calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_5baa6f06-d5c1-e7d5-57ec-bd3b80e4bef6" xlink:to="loc_us-gaap_Goodwill_d1288432-0516-3188-e96b-2bc623375a5a" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_BusinsessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities" xlink:label="loc_abus_BusinsessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities_9d7274dd-da7e-cdcd-cafc-ef6337766903" xlink:type="locator" />
    <calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_5baa6f06-d5c1-e7d5-57ec-bd3b80e4bef6" xlink:to="loc_abus_BusinsessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities_9d7274dd-da7e-cdcd-cafc-ef6337766903" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_f7ff0ef9-3907-f619-c985-f9387c2b8b2e" xlink:type="locator" />
    <calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_5baa6f06-d5c1-e7d5-57ec-bd3b80e4bef6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_f7ff0ef9-3907-f619-c985-f9387c2b8b2e" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_e0905149-e955-96b0-6abe-a8cc2f161e28" xlink:type="locator" />
    <calculationArc order="9" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_5baa6f06-d5c1-e7d5-57ec-bd3b80e4bef6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_e0905149-e955-96b0-6abe-a8cc2f161e28" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncSummaryOfAcquiredIdentifiableIntangibleAssetsDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/NatureOfBusinessAndFutureOperations" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/NatureOfBusinessAndFutureOperationsNarrativeDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/PropertyAndEquipment" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/PropertyAndEquipmentDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/PropertyAndEquipmentPropertyAndEquipmentSummaryDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/PropertyAndEquipmentTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/ShareCapital" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/ShareCapitalBlackScholesOptionPricingAssumptionsDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/ShareCapitalDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/ShareCapitalLocationOfExpensesForStockBasedCompensationDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/ShareCapitalNonVestedStockOptionActivityDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/ShareCapitalNonVestedStockOptionActivityOncoreOptionPlanDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/ShareCapitalOutstandingOptionsUnderOncoreOptionPlanDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/ShareCapitalOutstandingOptionsUnderProtivaOptionPlanDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/ShareCapitalStockOptionActivityDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/ShareCapitalStockOptionsOutstandingDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/ShareCapitalSummaryOfWarrantActivityDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/ShareCapitalTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/ShareCapitalWeightedAverageOptionPricingAssumptionsDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/SignificantAccountingPolicies" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_8b55b75a-d66d-1dbb-a26a-c58c1cb8c8b0" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1b16e3b5-4267-805c-bc8d-0fbc8ca9b0da" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_8b55b75a-d66d-1dbb-a26a-c58c1cb8c8b0" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1b16e3b5-4267-805c-bc8d-0fbc8ca9b0da" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_c834eacb-13fa-94c9-344e-6c3e507eff22" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_8b55b75a-d66d-1dbb-a26a-c58c1cb8c8b0" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_c834eacb-13fa-94c9-344e-6c3e507eff22" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments_c62110c4-28c7-e8eb-2a6d-e8964607a348" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_8b55b75a-d66d-1dbb-a26a-c58c1cb8c8b0" xlink:to="loc_us-gaap_LongTermInvestments_c62110c4-28c7-e8eb-2a6d-e8964607a348" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureRecurring" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureRecurring_f80fe47d-2734-e6b6-3064-c1fcdf2dcb97" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_10e4f07a-452f-c83d-9b21-0f27fc5e3c69" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureRecurring_f80fe47d-2734-e6b6-3064-c1fcdf2dcb97" xlink:to="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_10e4f07a-452f-c83d-9b21-0f27fc5e3c69" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_2f75413a-0715-3e2a-7260-1e1c79d9f7ef" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureRecurring_f80fe47d-2734-e6b6-3064-c1fcdf2dcb97" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_2f75413a-0715-3e2a-7260-1e1c79d9f7ef" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueConcentrationOfRiskDerivativeFinancialInstrumentsLiabilities" xlink:label="loc_us-gaap_FairValueConcentrationOfRiskDerivativeFinancialInstrumentsLiabilities_20ad9326-5aff-435e-b0c6-939122f423a7" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureRecurring_f80fe47d-2734-e6b6-3064-c1fcdf2dcb97" xlink:to="loc_us-gaap_FairValueConcentrationOfRiskDerivativeFinancialInstrumentsLiabilities_20ad9326-5aff-435e-b0c6-939122f423a7" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesChangesInFairValueOfCompanysWarrantsDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesChangesInFairValueOfContingentConsiderationDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesComputationOfBasicAndDilutedNetIncomeLossPerCommonShareDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesEstimatedUsefulLivesDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/SubsequentEvents" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/SubsequentEventsDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/SupplementaryInformation" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/SupplementaryInformationDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_771fda46-ad18-43f7-74a8-24b4258a1976" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_3e363941-50d5-576d-93bf-bcf41fd83617" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_771fda46-ad18-43f7-74a8-24b4258a1976" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent_3e363941-50d5-576d-93bf-bcf41fd83617" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_AccruedResearchandDevelopmentCurrent" xlink:label="loc_abus_AccruedResearchandDevelopmentCurrent_879547B33F4FA2533F0633FB67209E57" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_771fda46-ad18-43f7-74a8-24b4258a1976" xlink:to="loc_abus_AccruedResearchandDevelopmentCurrent_879547B33F4FA2533F0633FB67209E57" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_AccruedLicenseFeeCurrent" xlink:label="loc_abus_AccruedLicenseFeeCurrent_912ACD57762A3213D2C033FD9B2EA6E5" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_771fda46-ad18-43f7-74a8-24b4258a1976" xlink:to="loc_abus_AccruedLicenseFeeCurrent_912ACD57762A3213D2C033FD9B2EA6E5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_28c626c7-9023-e30f-2e48-0f4dd115d912" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_771fda46-ad18-43f7-74a8-24b4258a1976" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_28c626c7-9023-e30f-2e48-0f4dd115d912" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeaseIncentivePayableCurrent" xlink:label="loc_us-gaap_LeaseIncentivePayableCurrent_7cf1cbd8-570e-ba27-e267-e28a9ead2b2e" xlink:type="locator" />
    <calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_771fda46-ad18-43f7-74a8-24b4258a1976" xlink:to="loc_us-gaap_LeaseIncentivePayableCurrent_7cf1cbd8-570e-ba27-e267-e28a9ead2b2e" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_AccruedPayrollCurrent" xlink:label="loc_abus_AccruedPayrollCurrent_90EC98AAC74548078C6F3401C80755EA" xlink:type="locator" />
    <calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_771fda46-ad18-43f7-74a8-24b4258a1976" xlink:to="loc_abus_AccruedPayrollCurrent_90EC98AAC74548078C6F3401C80755EA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_46c5e103-584b-b600-2852-4201435cc29f" xlink:type="locator" />
    <calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_771fda46-ad18-43f7-74a8-24b4258a1976" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_46c5e103-584b-b600-2852-4201435cc29f" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/SupplementaryInformationTables" xlink:type="extended" />
</linkbase>





